Neutrophilic leukocytosis in advanced stage polycythemia vera: Hematopathologic features and prognostic implications

Leonardo Boiocchi, Umberto Gianelli, Alessandra Iurlo, Falko Fend, Irina Bonzheim, Daniele Cattaneo, Daniel M. Knowles, Attilio Orazi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Polycythemia vera in 20-30% of cases progresses towards post-polycythemic myelofibrosis, an advanced phase characterized by decreased red blood cells counts and increasing splenomegaly with extramedullary hematopoiesis. There is evidence that the presence of neutrophilic leukocytosis at polycythemia vera disease outset is associated with an increased risk of recurrent thrombosis. However, its clinical significance when developing later in the course of the disease is not well defined. Over a period of 8 years we identified from the files of two reference centers 10 patients (7M/3F, median age: 68 years) who developed persistent absolute leukocytosis ≥13 × 10 9 /l (median: 25.1 × 10 9 /l; range: 16.1-89.7 × 10 9 /l) at or around the time of diagnosis of post-polycythemic myelofibrosis (median interval from diagnosis:0 months; range: -6/31) and persisted for a median period of 13 months. Peripheral blood smears showed numerous neutrophils without dysplastic features and, in four, ≥10% immature myeloid precursors. In five cases, corresponding marrow specimens obtained at or immediately after the onset of leukocytosis showed a markedly increased myeloid:erythroid ratio due to granulocytic proliferation. No change in JAK2 and BCR-ABL1 status or cytogenetic evolution was associated with the development of leukocytosis. The mutational status of CSF3R, SETBP1, and SRSF2, genes associated with other chronic myeloid neoplasms where neutrophilic leukocytosis occurs, was investigated but all cases showed wild-type only alleles. Four patients died after developing leukocytosis and one experienced worsening disease. Compared with a control group of post-polycythemic myelofibrosis patients (n=23) who never developed persistent leukocytosis, patients with leukocytosis showed higher white blood cells counts and a shorter overall survival. This is the first study describing the development of significant neutrophilic leukocytosis during advanced stages of polycythemia vera; it includes comprehensive hematologic, marrow morphological, molecular, and clinical data. Our findings suggest that persistent leukocytosis occurring at or around the time of progression to post-polycythemic myelofibrosis is associated with an overall more aggressive course of the disease.

Original languageEnglish
Pages (from-to)1448-1457
Number of pages10
JournalModern Pathology
Volume28
Issue number11
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Polycythemia Vera
Leukocytosis
Primary Myelofibrosis
Bone Marrow
Extramedullary Hematopoiesis
Erythrocyte Count
Splenomegaly
Leukocyte Count
Cytogenetics
Neutrophils
Thrombosis
Alleles

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Neutrophilic leukocytosis in advanced stage polycythemia vera : Hematopathologic features and prognostic implications. / Boiocchi, Leonardo; Gianelli, Umberto; Iurlo, Alessandra; Fend, Falko; Bonzheim, Irina; Cattaneo, Daniele; Knowles, Daniel M.; Orazi, Attilio.

In: Modern Pathology, Vol. 28, No. 11, 01.11.2015, p. 1448-1457.

Research output: Contribution to journalArticle

Boiocchi, Leonardo ; Gianelli, Umberto ; Iurlo, Alessandra ; Fend, Falko ; Bonzheim, Irina ; Cattaneo, Daniele ; Knowles, Daniel M. ; Orazi, Attilio. / Neutrophilic leukocytosis in advanced stage polycythemia vera : Hematopathologic features and prognostic implications. In: Modern Pathology. 2015 ; Vol. 28, No. 11. pp. 1448-1457.
@article{fd62fd71db5446ae91998fe2406c74e4,
title = "Neutrophilic leukocytosis in advanced stage polycythemia vera: Hematopathologic features and prognostic implications",
abstract = "Polycythemia vera in 20-30{\%} of cases progresses towards post-polycythemic myelofibrosis, an advanced phase characterized by decreased red blood cells counts and increasing splenomegaly with extramedullary hematopoiesis. There is evidence that the presence of neutrophilic leukocytosis at polycythemia vera disease outset is associated with an increased risk of recurrent thrombosis. However, its clinical significance when developing later in the course of the disease is not well defined. Over a period of 8 years we identified from the files of two reference centers 10 patients (7M/3F, median age: 68 years) who developed persistent absolute leukocytosis ≥13 × 10 9 /l (median: 25.1 × 10 9 /l; range: 16.1-89.7 × 10 9 /l) at or around the time of diagnosis of post-polycythemic myelofibrosis (median interval from diagnosis:0 months; range: -6/31) and persisted for a median period of 13 months. Peripheral blood smears showed numerous neutrophils without dysplastic features and, in four, ≥10{\%} immature myeloid precursors. In five cases, corresponding marrow specimens obtained at or immediately after the onset of leukocytosis showed a markedly increased myeloid:erythroid ratio due to granulocytic proliferation. No change in JAK2 and BCR-ABL1 status or cytogenetic evolution was associated with the development of leukocytosis. The mutational status of CSF3R, SETBP1, and SRSF2, genes associated with other chronic myeloid neoplasms where neutrophilic leukocytosis occurs, was investigated but all cases showed wild-type only alleles. Four patients died after developing leukocytosis and one experienced worsening disease. Compared with a control group of post-polycythemic myelofibrosis patients (n=23) who never developed persistent leukocytosis, patients with leukocytosis showed higher white blood cells counts and a shorter overall survival. This is the first study describing the development of significant neutrophilic leukocytosis during advanced stages of polycythemia vera; it includes comprehensive hematologic, marrow morphological, molecular, and clinical data. Our findings suggest that persistent leukocytosis occurring at or around the time of progression to post-polycythemic myelofibrosis is associated with an overall more aggressive course of the disease.",
author = "Leonardo Boiocchi and Umberto Gianelli and Alessandra Iurlo and Falko Fend and Irina Bonzheim and Daniele Cattaneo and Knowles, {Daniel M.} and Attilio Orazi",
year = "2015",
month = "11",
day = "1",
doi = "10.1038/modpathol.2015.100",
language = "English",
volume = "28",
pages = "1448--1457",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Neutrophilic leukocytosis in advanced stage polycythemia vera

T2 - Hematopathologic features and prognostic implications

AU - Boiocchi, Leonardo

AU - Gianelli, Umberto

AU - Iurlo, Alessandra

AU - Fend, Falko

AU - Bonzheim, Irina

AU - Cattaneo, Daniele

AU - Knowles, Daniel M.

AU - Orazi, Attilio

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Polycythemia vera in 20-30% of cases progresses towards post-polycythemic myelofibrosis, an advanced phase characterized by decreased red blood cells counts and increasing splenomegaly with extramedullary hematopoiesis. There is evidence that the presence of neutrophilic leukocytosis at polycythemia vera disease outset is associated with an increased risk of recurrent thrombosis. However, its clinical significance when developing later in the course of the disease is not well defined. Over a period of 8 years we identified from the files of two reference centers 10 patients (7M/3F, median age: 68 years) who developed persistent absolute leukocytosis ≥13 × 10 9 /l (median: 25.1 × 10 9 /l; range: 16.1-89.7 × 10 9 /l) at or around the time of diagnosis of post-polycythemic myelofibrosis (median interval from diagnosis:0 months; range: -6/31) and persisted for a median period of 13 months. Peripheral blood smears showed numerous neutrophils without dysplastic features and, in four, ≥10% immature myeloid precursors. In five cases, corresponding marrow specimens obtained at or immediately after the onset of leukocytosis showed a markedly increased myeloid:erythroid ratio due to granulocytic proliferation. No change in JAK2 and BCR-ABL1 status or cytogenetic evolution was associated with the development of leukocytosis. The mutational status of CSF3R, SETBP1, and SRSF2, genes associated with other chronic myeloid neoplasms where neutrophilic leukocytosis occurs, was investigated but all cases showed wild-type only alleles. Four patients died after developing leukocytosis and one experienced worsening disease. Compared with a control group of post-polycythemic myelofibrosis patients (n=23) who never developed persistent leukocytosis, patients with leukocytosis showed higher white blood cells counts and a shorter overall survival. This is the first study describing the development of significant neutrophilic leukocytosis during advanced stages of polycythemia vera; it includes comprehensive hematologic, marrow morphological, molecular, and clinical data. Our findings suggest that persistent leukocytosis occurring at or around the time of progression to post-polycythemic myelofibrosis is associated with an overall more aggressive course of the disease.

AB - Polycythemia vera in 20-30% of cases progresses towards post-polycythemic myelofibrosis, an advanced phase characterized by decreased red blood cells counts and increasing splenomegaly with extramedullary hematopoiesis. There is evidence that the presence of neutrophilic leukocytosis at polycythemia vera disease outset is associated with an increased risk of recurrent thrombosis. However, its clinical significance when developing later in the course of the disease is not well defined. Over a period of 8 years we identified from the files of two reference centers 10 patients (7M/3F, median age: 68 years) who developed persistent absolute leukocytosis ≥13 × 10 9 /l (median: 25.1 × 10 9 /l; range: 16.1-89.7 × 10 9 /l) at or around the time of diagnosis of post-polycythemic myelofibrosis (median interval from diagnosis:0 months; range: -6/31) and persisted for a median period of 13 months. Peripheral blood smears showed numerous neutrophils without dysplastic features and, in four, ≥10% immature myeloid precursors. In five cases, corresponding marrow specimens obtained at or immediately after the onset of leukocytosis showed a markedly increased myeloid:erythroid ratio due to granulocytic proliferation. No change in JAK2 and BCR-ABL1 status or cytogenetic evolution was associated with the development of leukocytosis. The mutational status of CSF3R, SETBP1, and SRSF2, genes associated with other chronic myeloid neoplasms where neutrophilic leukocytosis occurs, was investigated but all cases showed wild-type only alleles. Four patients died after developing leukocytosis and one experienced worsening disease. Compared with a control group of post-polycythemic myelofibrosis patients (n=23) who never developed persistent leukocytosis, patients with leukocytosis showed higher white blood cells counts and a shorter overall survival. This is the first study describing the development of significant neutrophilic leukocytosis during advanced stages of polycythemia vera; it includes comprehensive hematologic, marrow morphological, molecular, and clinical data. Our findings suggest that persistent leukocytosis occurring at or around the time of progression to post-polycythemic myelofibrosis is associated with an overall more aggressive course of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84946496325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946496325&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2015.100

DO - 10.1038/modpathol.2015.100

M3 - Article

C2 - 26336886

AN - SCOPUS:84946496325

VL - 28

SP - 1448

EP - 1457

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 11

ER -